Other Significant Adverse Events in Clinical Study Report
ICH E3 section 12.3.1.3 distinguishes other significant adverse events from deaths and other serious adverse events for focused safety reporting. Do not merge this category with all adverse events, deaths, or other serious adverse events; ICH E3 gives these safety groupings separate reporting roles.
ReviewedEvidence1 sourceSectionWriting & Style
Quick answer
This subsection identifies clinically important adverse events that warrant focused review even when they are not classified in the dedicated death or other-serious-event categories.
Key details
Core IssueICH E3 section 12.3.1.3 distinguishes other significant adverse events from deaths and other serious adverse events for focused safety reporting.
Registerscholarly, professional, or research/report writing
Important caveats
Scope Boundary
Do not merge this category with all adverse events, deaths, or other serious adverse events; ICH E3 gives these safety groupings separate reporting roles.
Further guidance
Content
Define the study-relevant basis for treating an event as otherwise significant and present the patient-level information needed to understand those cases.
Purpose
This subsection identifies clinically important adverse events that warrant focused review even when they are not classified in the dedicated death or other-serious-event categories.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
ICH E3 section 12.3.3 calls for analysis and discussion across deaths, other serious adverse events, and other significant adverse events after the relevant case listings and narratives. This is an interpretive synthesis, not a duplicate death/serious-event listing or a replacement for individual patient narratives.
ICH E3 section 12.2.3 calls for analysis of adverse events beyond their tabular display, focusing on patterns important to safety interpretation. Do not treat the analysis as a substitute for the event display or patient-level listing, and do not imply causality beyond what the study evidence supports.
ICH E3 section 12.2.1 calls for a brief summary of adverse events within the safety evaluation before more detailed displays and analyses. Keep this section a high-level summary; it is not a substitute for detailed adverse-event displays, patient-level listings, serious-event treatment, or narratives.
ICH E3 section 12.2.2 provides for structured display of adverse events as part of the clinical study report safety evaluation. A summary display is distinct from patient-level adverse-event listings and from narratives of selected serious or otherwise significant cases.
ICH E3 requires other serious adverse events to receive focused safety reporting, including patient-level listing and narrative treatment when needed to understand the event and its relationship to study treatment. ICH E3 distinguishes deaths from other serious adverse events for listing purposes; a fatal serious event may be referenced in both contexts, so counting and cross-references must remain clear.
ICH E3 places patient-level adverse-event listings in the report appendices and calls for listings that identify individual patients and relevant event details supporting review. A listing is not the same as a summary adverse-event table or a selected patient narrative; each serves a different level of safety reporting.
ICH E3 section 12.4.2.3 calls for discussion and analysis of individual clinically significant laboratory abnormalities, including assessment of clinical significance and likely treatment relationship. This is not a listing of every abnormal value: the focus is on clinically significant changes and their interpretation within the ICH E3 safety framework.
ICH E3 section 12.4.1 points to a by-patient listing of abnormal laboratory values in section 14.3.4 and distinguishes that safety display from the broader listing of individual laboratory measurements. This page is about the dedicated abnormal-value listing under ICH E3 14.3.4; it is distinct from the full individual-measurement appendix under 16.2.8 and from analytical discussion in section 12.4.2.
